// App-Quantinova.ai

272 : Long-Term Efficacy of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Bdmards: Results from RA-BEYOND up to 6.9-Years of Treatment

Researchers

Presenter

  • Daniel Aletaha

Principal Investigators

  • Roberto Caporali

  • Raimon Sanmarti

  • Tsutomu Takeuchi

  • DAOJUN MO

  • Ewa Haladyj

  • Liliana Zaremba-Pechmann

  • Peter Taylor

Medical Centers

  • Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Montu Beccaria, Italy

  • Medical University of Vienna, Vienna, Austria

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Keio University and Saitama Medical University, Tokyo, Japan

  • Eli Lilly and Company, Carmel, IN

  • Eli Lilly and Company, Warszawa, Poland

  • HaaPACS GmbH, Schriesheim, Germany

  • University of Oxford, Oxford, United Kingdom

Locations

  • Italy

  • Austria

  • Spain

  • Japan

  • United States

  • Poland

  • Germany

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved